Soy phytoestrogens may block estrogen effectsJanuary 16, 2006Research in monkeys suggests that the natural plant estrogens found in soy do not increase markers of breast cancer risk in postmenopausal women. In fact, they may provide a protective effect in some women. The research is reported today in Cancer Research. "Even at high doses, we found no evidence that the estrogen-like compounds in soy, called isoflavones, stimulate cell growth or other markers for cancer risk in breast tissue," said Charles E. Wood, D.V.M., Ph.D., lead researcher, from Wake Forest University Baptist Medical Center. "The study also suggests that women who have higher levels of estrogen may actually gain a protective effect from higher doses of soy isoflavones." Wood said there has been much debate about whether higher levels of dietary soy are safe or beneficial for postmenopausal women. Some evidence has suggested that isoflavones may protect against the more powerful estrogen produced by the body, which is an important risk factor for breast cancer in postmenopausal women. For example, population studies show that women who consume diets high in soy generally have lower rates of breast cancer. On the other hand, soy isoflavones have been shown to stimulate breast cancer cells in mice and in cells grown in the laboratory. "Our study sought to make sense of these seemingly contradictory data," said Wood. "Our hypothesis was that estrogen levels in the body may influence the effects of soy isoflavones." Wood and colleagues evaluated the effects of dietary isoflavones in the presence of different levels of estrogen by rotating 31 postmenopausal cynomolgus monkeys through eight different diets. Each diet contained one of four different isoflavone doses along with either a low or a high dose of estrogen. Isoflavone doses were equivalent to the following human levels: no isoflavones, 60 milligrams (comparable to the typical Asian diet), 120 milligrams (the highest levels that can be consumed through diet alone), or 240 milligrams (levels obtained through supplements). Estrogen doses were designed to mimic either a low or high-estrogen environment found in postmenopausal women. Estrogen levels in postmenopausal women can vary depending on their amounts of body fat, which produces estrogen, and whether they are taking hormone therapy. The researchers measured how the diets affected markers for breast cancer risk, including breast cell proliferation. In the low-estrogen environment, no evidence of increased proliferation was seen at any level of isoflavone exposure, even at doses almost several times higher than in a typical Asian diet. In the high-estrogen environment, there was higher breast cell proliferation both when isoflavones weren't in the diet and when they were present in lower doses. However, the addition of high levels of dietary soy isoflavones tended to block estrogen effects in breast tissue. This finding suggests that postmenopausal women with higher levels of estrogen may derive the greatest benefit from soy. "For women at increased risk of breast cancer due to higher estrogen levels, a diet rich in soy isoflavones may offer a modest breast-protective effect," said Wood. However, he said the study may not apply to premenopausal women, who have higher and more dynamic hormone levels, or to women taking combined hormone therapy with an estrogen and a progestin. The senior investigator of the study was J. Mark Cline, D.V.M., Ph.D. Other researchers involved in the study were Thomas C. Register, Ph.D., and Mary S. Anthony, Ph.D., both from Wake Forest Baptist, and Adrian A. Franke, Ph.D., from the Cancer Center of Hawaii. Wake Forest University Baptist Medical Center |
|||||||||||||||||||||
| Related Estrogen Current Events and Estrogen News Articles Heart and bone damage from low vitamin D tied to declines in sex hormones Researchers at Johns Hopkins are reporting what is believed to be the first conclusive evidence in men that the long-term ill effects of vitamin D deficiency are amplified by lower levels of the key sex hormone estrogen, but not testosterone. Fertility procedures need not delay breast cancer treatment for younger women A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion. Coffee break: Compound brewing new research in colon, breast cancer A compound in coffee has been found to be estrogenic in studies by Texas AgriLife Research scientists. Mayo researchers find robotic repair for vaginal prolapse has significant benefits New Mayo Clinic research has found that robotic surgery for vaginal prolapse dramatically reduces patient hospital stay and recovery time. Estrogen therapy likely must be given soon after menopause to provide stroke protection For estrogen replacement to provide stroke protection, it likely must be given soon after levels drop because of menopause or surgical removal of the ovaries, scientists report in the Journal of Neuroscience. Oral contraceptives may benefit women with asthma New research shows that during natural menstrual cycles, women with asthma who were not taking oral contraceptives (OC) had lower exhaled nitric oxide levels (eNO), a marker of airway inflammation associated with asthma, than women who were taking OC. Study shows hormone replacement therapy decreases mortality in younger postmenopausal woman Hormone replacement therapy (HRT) to treat menopausal estrogen deficiency has been in widespread use for over 60 years. Several observational studies over the years showed that HRT use by younger postmenopausal women was associated with a significant reduction in total mortality; available evidence supported the routine use of HRT to increase longevity in postmenopausal women. Hormone mix could cut breast cancer risk and treat symptoms of menopause The right combination of estrogen and a selective estrogen receptor modulator (SERM), which blocks the effects of estrogen in breast tissue, could relieve menopause symptoms and cut breast cancer risk. Breast tenderness during hormone replacement therapy linked to elevated cancer risk Women who developed new-onset breast tenderness after starting estrogen plus progestin hormone replacement therapy were at significantly higher risk for developing breast cancer than women on the combination therapy who didn't experience such tenderness, according to a new UCLA study. Study finds no relationship between PCR rate and race in women with breast cancer Locally advanced breast cancer patients who received the same class of neoadjuvant chemotherapy were found to have no evidence of disease at the time of their surgery, or achieved pathological complete response, at the same rate regardless of race, according to researchers at The University of Texas M. D. Anderson Cancer Center. More Estrogen Current Events and Estrogen News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||